Lecanemab reduces brain amyloid-β and delays cognitive worsening.
rct · Level I
Where this comes from
- Record sourced from PubMed, PMID 36948153.
- Also identified by DOI 10.1016/j.xcrm.2023.100982 and PMC identifier 10040446.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Lecanemab cleared amyloid-β in two-thirds and reduced the rate of cognitive and functional worsening in people with mild cognitive impairment and mild dementia due to Alzheimer disease in an 18-month double-blinded randomized placebo-controlled trial reported by van Dyck et al.
Medical subject headings
- Alzheimer Disease
- Amyloid beta-Peptides